References
- WHO . www.who.int/mediacentre/factsheets/fs360/en/
- Caskey M , KleinF, LorenziJCet al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature522, 487–491 (2015).
- Menéndez-Arias L . Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments. Antiviral Res.98 (1), 93–120 (2013).
- Wilton J , SennH, SharmaMet al. Pre-exposure prophylaxis for sexually-acquired HIV risk management: a review. HIV AIDS (Auckl)7, 125–36 (2015).
- Lloyd SB , KentSJ, WinnallWR. The high cost of fidelity. AIDS Res. Hum. Retroviruses30 (1), 8–16 (2014).
- Hu WS , HughesSH. HIV-1 reverse transcription. Cold Spring Harb. Perspect. Med.2 (10), a006882 (2012).
- Santoro MM , PernoCF. HIV-1 genetic variability and clinical implications. ISRN Microbiol.2013, 481314 (2013).
- Wensing M , CalvezV, GunthardHFet al. 2014 update of the drug resistance mutations in HIV-1. Top. Antivir. Med.22, 642–650 (2014).
- Prosperi MC , De LucaA. Computational models for prediction of response to antiretroviral therapies. AIDS Rev.14 (2), 145–53 (2012).
- Yu X , WeberIT, HarrisonRW. Prediction of HIV drug resistance from genotype with encoded three-dimensional protein structure. BMC Genom.15 (Suppl. 5), S1 (2014).
- Van Laethem K , TheysK, VandammeAM. HIV-1 genotypic drug resistance testing: digging deep, reaching wide?Curr. Opin. Virol.14, 16–23 (2015).
- Das K , ArnoldE. HIV-1 reverse transcriptase and antiviral drug resistance. Part 1. Curr. Opin. Virol.3 (2), 111–118 (2013).
- Das K , ArnoldE. HIV-1 reverse transcriptase and antiviral drug resistance. Part 2. Curr. Opin. Virol.3 (2), 119–128 (2013).
- Konvalinka J , KrausslichHG, MullerB. Retroviral proteases and their roles in virion maturation. Virology479–480C, 403–417 (2015).
- Lee SK , PotempaM, SwanstromR. The choreography of HIV-1 proteolytic processing and virion assembly. J. Biol. Chem.287 (49), 40867–40874 (2012).
- Weber IT , KnellerDW, Wong-SamA. Highly resistant HIV-1 proteases and strategies for their inhibition. Future Med. Chem.7, 1023–1038 (2015).
- Ghosh AK , AndersonDD, WeberITet al. Enhancing protein backbone binding – a fruitful concept for combating drug-resistant HIV. Angew. Chem. Int. Ed. Engl.51 (8), 1778–802 (2012).
- Malet I , CalvezV, MarcelinAG. The future of integrase inhibitors of HIV-1. Curr. Opin. Virol.2 (5), 580–587 (2012).
- Mesplède T , WainbergMA. Resistance against integrase strand transfer inhibitors and relevance to HIV persistence. Viruses7 (7), 3703–3718 (2015).
- Christ F , DebyserZ. The LEDGF/p75 integrase interaction, a novel target for anti-HIV therapy. Virology435 (1), 102–109 (2013).